In­cyte links arms with tiny Bio­th­eryx for pro­tein de­grad­er deal, tar­get­ing can­cer

In­cyte is jump­ing in on Bio­th­eryx’s plat­form, look­ing for po­ten­tial pro­tein de­graders for a new, undis­closed on­col­o­gy tar­get.

The deal, an­nounced Wednes­day morn­ing, will see Bio­th­eryx re­ceive $7 mil­lion as a tech ac­cess fee, plus an ad­di­tion­al $6 mil­lion in po­ten­tial R&D back­ing. Mile­stones could add up to $347 mil­lion.

While the deal is cur­rent­ly on­ly for one tar­get, it could be ex­pand­ed with the same fi­nan­cial num­bers to oth­er new can­cer tar­gets, Bio­th­eryx CEO Philippe Drou­et tells End­points News. If In­cyte choos­es to work with Bio­th­eryx on a sec­ond tar­get, for ex­am­ple, In­cyte would have to pay an­oth­er $7 mil­lion tech ac­cess fee, along with the po­ten­tial R&D fund­ing and the nine-fig­ure po­ten­tial in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER